Certa Health Limited

Certa Health Limited is a small, active company based in Milton Keynes, UK, founded seven years ago in 2018. Despite its active status, the company has overdue accounts for two years and confirmation statements for three years. It employs just one person and is led by a single director and owner, who is also the solo founder. The company operates in the retail sale via mail order houses or via internet industries.

The company’s website reveals a focus on developing innovative therapies for inflammatory and fibrotic diseases. Certa Therapeutics is actively researching treatments for conditions like scleroderma, chronic kidney disease, and diabetic nephropathy. The site highlights a pipeline of scientific research, including a focus on GPR68 inhibitors, and features news updates, including acquisitions and partnerships. It’s clear that Certa Therapeutics is not a standard e-commerce operation; it’s a research-driven pharmaceutical company.

Financially, Certa Health Limited’s numbers paint a concerning picture. Net current assets liabilities have fallen dramatically, dropping 100% to zero. Trade debtors have also plummeted, falling 100% to zero. Equity has seen a significant decrease, with retained earnings and accumulated losses declining to -£100. While creditors have also decreased, the overall trend suggests the company is burning through cash. The company’s small size (meeting two of three criteria for turnover under £10.2m, assets under £5.1m, and fewer than 50 employees) means it may struggle to secure external funding. With no auditor mentioned, the unaudited figures require careful interpretation. It's possible that the company is in a crucial phase of research and development, which often requires significant upfront investment before generating revenue—but the sharp decline in assets is something to watch.

Registered in England/Wales under the registration number 11246540, with a registered address at MK2 2DD, Milton Keynes, Claydon House, 21 Simpson Road.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.